NASDAQ:KERX - Keryx Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.36 +3.36 (+∞)
(As of 12/12/2018)
Previous Close$3.36
Today's Range$2.9650 - $3.4650
52-Week Range$2.47 - $5.98
Volume2.60 million shs
Average Volume1.69 million shs
Market Capitalization$344.00 million
P/E RatioN/A
Dividend YieldN/A
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Receive KERX News and Ratings via Email

Sign-up to receive the latest news and ratings for KERX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KERX



Sales & Book Value

Annual Sales$60.64 million
Book Value($0.12) per share


Net Income$-163,440,000.00


Market Cap$344.00 million
Next Earnings DateN/A

Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals (NASDAQ:KERX) posted its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analysts' expectations of $29.56 million. View Keryx Biopharmaceuticals' Earnings History.

What price target have analysts set for KERX?

5 analysts have issued 12-month price objectives for Keryx Biopharmaceuticals' stock. Their forecasts range from $4.00 to $9.00. On average, they anticipate Keryx Biopharmaceuticals' stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price. View Analyst Price Targets for Keryx Biopharmaceuticals.

What is the consensus analysts' recommendation for Keryx Biopharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keryx Biopharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Keryx Biopharmaceuticals.

What are Wall Street analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Valuation compelling. Keryx stock price has pulled back since the merger was announced in June, losing 33% of its value versus the XBI Biotech index losing only 9%. However we see only improving fundamentals as Auryxia revenues continue to improve QoQ." (11/9/2018)
  • 2. Maxim Group analysts commented, "Keryx reported 3Q18 with total revenue of $28.0M, a slight miss from the consensus estimate of $29.1M. US Auryxia sales for the quarter were $26.6M up 11% q/q, driven by increased RX volume. The company reported a net loss of ($17.0M) and ended the quarter with $41.1M in cash." (11/9/2018)
  • 3. According to Zacks Investment Research, "Keryx is completely dependent on Auryxia for growth as it is the only approved product in the company’s portfolio. Auryxia faces stiff competition in the United States from existing players. Shares of the company have underperformed the industry so far this year.  However, Keryx's launch of Auryxia for the second indication — iron deficiency anemia (IDA) in chronic kidney disease patients — is boosting sales of the company, given that the IDA market holds great potential. Keryx entered a definitive merger agreement with Akebia Therapeutics that will create a fully integrated company focused on the development and commercialization of therapeutics for patients with chronic kidney diseases. The combined company will be well positioned to create significant shareholder value and accelerate growth beyond what either company would achieve separately. Loss estimates have remained stable ahead of Q3 earnings release." (10/9/2018)

Has Keryx Biopharmaceuticals been receiving favorable news coverage?

News articles about KERX stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Keryx Biopharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.

Who are some of Keryx Biopharmaceuticals' key competitors?

What other stocks do shareholders of Keryx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), Amyris (AMRS), Exelixis (EXEL), Celgene (CELG), Nektar Therapeutics (NKTR), Novavax (NVAX), Dynavax Technologies (DVAX), Ariad Pharmaceuticals (ARIA) and Inovio Pharmaceuticals (INO).

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the folowing people:
  • Ms. Jodie Pope Morrison, Interim CEO & Director (Age 43)
  • Mr. Scott A. Holmes, CFO, Sr. VP & Treasurer (Age 44)
  • Ms. Christine A. Carberry, Sr. VP & COO (Age 57)
  • Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Tony Chambers, VP of Sales

How do I buy shares of Keryx Biopharmaceuticals?

Shares of KERX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Keryx Biopharmaceuticals' stock price today?

One share of KERX stock can currently be purchased for approximately $3.36.

How big of a company is Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals has a market capitalization of $344.00 million and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

What is Keryx Biopharmaceuticals' official website?

The official website for Keryx Biopharmaceuticals is

How can I contact Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected]

MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  477 (Vote Outperform)
Underperform Votes:  334 (Vote Underperform)
Total Votes:  811
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KERX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KERX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel